Table 1 Demographic and PID features of 28 children receiving weekly (Q1W) or biweekly (Q2W) Hizentra^® treatment

Gender (male)

11 (74.3%)

10 (76.9%)

RR = 1.05 (0.73–1.51)

21 (75.0%)

Age (years)

11.9 ± 4.6 (13; 11–15)

11.5 ± 4.1 (13; 9–14)

Δ = − 0.33 (− 2.99 to 2.33)

11.7 ± 4.3 (13; 10–15)

Height (cm)

148.4 ± 27.8 (157; 138–167)

148.5 ± 24.7 (159; 138–165)

Δ = 0.03 (− 15.97 to 16.02)

148.4 ± 25.9 (158; 136–166)

Weight (kg)

50.3 ± 22.6 (55; 33–63)

47.4 ± 19.8 (47; 34–61)

Δ = − 2.85 (− 15.77 to 10.06)

48.9 ± 21 (49; 33–62)

BMI (kg/m²)

21.4 ± 4.7 (23; 17–24)

20.5 ± 4.9 (19; 18–24)

Δ = − 0.82 (− 3.75 to 2.11)

21 ± 4.7 (20; 17–24)

Serum IgG trough levels before Hizentra^® use (g/L)

8.2 ± 1.1 (8.3; 7–9)

8.6 ± 2.6 (7.7; 7–10)

Δ = 0.40 (− 1.29 to 2.08)

8.3 ± 1.6 (8.1; 7–9)